The human papillomaviruses (HPV) are the etiologic agents of 60-70% of head and neck squamous cell carcinoma (HNSCC) arising from the oropharynx. Approximately 70% of patients with HPV+ HNSCC are cured with aggressive therapy that may result in lifelong side effects. Upon recurrence, treatment options and survival are limited. Unique molecular and epigenetic features of HPV+ HNSCC provide an opportunity for targeted therapies. Here, we show that 5-azacytidine (5-aza) -a demethylating agent that is used to treat patients with hematologic malignanciesinhibited tumor growth and reduced HNSCC invasion in mouse models. 5-aza decreased expression of HPV genes accompanied by increased expression of p53 and apoptosis in both pre-clinical models, as well as following 5-7 days of 5-aza patient therapy in a window trial. These data suggest that demethylation therapy may be effective for treating HPV+ HNSCC and that a larger clinical trial is warranted. Conclusions: 5-aza may provide effective therapy for HPV-associated HNSCC as an alternative or complement to standard cytotoxic therapy.
Translational relevance
The human papillomaviruses (HPV) are the etiologic agents of 60-70% of head and neck squamous cell carcinoma (HNSCC) arising from the oropharynx. Approximately 70% of patients with HPV+ HNSCC are cured with aggressive therapy that may result in lifelong side effects. Upon recurrence, treatment options and survival are limited. Unique molecular and epigenetic features of HPV+ HNSCC provide an opportunity for targeted therapies. Here, we show that 5-azacytidine (5-aza) -a demethylating agent that is used to treat patients with hematologic malignanciesinhibited tumor growth and reduced HNSCC invasion in mouse models. 5-aza decreased expression of HPV genes accompanied by increased expression of p53 and apoptosis in both pre-clinical models, as well as following 5-7 days of 5-aza patient therapy in a window trial. These data suggest that demethylation therapy may be effective for treating HPV+ HNSCC and that a larger clinical trial is warranted.
Introduction
There is increasing evidence that human-papilloma virus (HPV)-associated cancers represent a unique disease entity separate from HPV-negative (HPV-) tumors. Demographic data reveal that HPV+ HNSCC occurs in younger patients with less tobacco and alcohol exposure (1, 2) . HPV+ head and neck primary tumors are usually smaller, as compared to HPV-HNSCC; however, patients with HPV-associated tumors are more likely to present with metastatic disease in regional lymph nodes (3, 4) . In addition, HPV+ HNSCC responds better to chemotherapy and radiation than HPV-HNSCC, and HPV-positivity is associated with improved overall survival (5) .
At the molecular level, HPV+ and HPV-head and neck cancers have different mutational landscapes and different protein expression profiles (6) (7) (8) (9) (10) . HPV-HNSCCs contain mutations and genetic alterations classically associated with tobacco and alcohol exposure, including loss of function mutations of TP53 (84%) and loss or inactivating mutations of CDKN2A (54%). In contrast, genetic alterations in these genes are extremely rare in the HPV+ subset (TP53 -3%;
CDKN2A -0%) (6) , which instead is associated with a mutational signature typical of apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3 (APOBEC3) antiviral proteins (6, (11) (12) (13) . In addition, The Cancer Genome Atlas (TCGA) head and neck study found that tumor necrosis factor receptor-associated factor 3 (TRAF3) and CYLD genes are commonly mutated and deleted in HPV+ HNSCC (6, 8, 14) . Finally, HPV-HNSCC have relatively low levels of DNA methylation, which is correlated with genomic instability (15) , while HPV+ HNSCC harbor distinctly hypermethylated genomes (7, 8, 16, 17) .
Demographic, clinical, molecular, and epigenetic differences between HPV+ and HPV-HNSCC suggest two distinct cancers, yet HPV-status is currently only used for prognosis and not to guide treatment (18) . A majority of HNSCC patients are treated with radiation and platin-based chemotherapy, which is associated with deleterious and lifelong side-effects. Despite the relatively good prognosis associated with HPV+ HNSCC, 25-30% of patients with HPV-positive tumors experience recurrent or metastatic disease, for which treatment options are limited.
The molecular and epigenetic differences between HPV+ and HPV-tumors provide an opportunity for therapies that exploit the interaction of the HPV genome and host that result in hypermethylation of cancer cell genomes. 5-azacytidine (5-aza) and its structural analog, 5-aza-2'-deoxycytidine (decitabine), are U.S. Food and Drug Administration (FDA) approved DNA demethylating agents used for therapy of myelodysplastic syndromes (MDS) and acute demethylation of the cellular genome (21) . Though known to demethylate DNA, the link between demethylation-induced transcription and the therapeutic effects of these drugs is not well established (21) . On one hand, demethylation can re-activate tumor suppressors that were repressed by promoter methylation, resulting in tumor suppressor-induced cancer cell death (22) .
On the other hand, demethylation of CpG loci within gene bodies can paradoxically decrease gene transcription (23) . Furthermore, 5-aza is incorporated into RNA (24, 25) , where it can alter mRNA stability (26) and therefore change expression independently of its effect on transcription.
Finally, 5-aza and decitabine cause DNA damage and activate the DNA damage response in some cells; however, the nature of this DNA damage has not been fully characterized and is likely cell type-dependent (27) .
Exploration of demethylating drugs for treatment of solid tumors is in the early stages with the highest response rates to decitabine occurring in cervical (36%) and pleural (14%) malignancies, but decitabine has not yet been tested in HNSCC (28) . Here, demethylation therapy was explored as a novel, targeted treatment for HPV+ HNSCC. We assessed the cellular response and effect on metastatic potential following demethylation therapy in HPV+ HNSCC cells, xenograft mouse models, and in clinical trial specimens from head and neck cancer patients (29). We demonstrated that HPV+ HNSCC cells were more sensitive to 5-azacytidine than were HPV-negative cells, and that sensitivity was at least partially due to reactivation of p53 in HPV+ tumors. 5-azacytidine treatment correlated with decreased expression of HPV genes and activated caspases in HPV+ HNSCC cells and patient tumors. In addition, 5-aza therapy significantly delayed growth of xenografted HPV+ HNSCC tumors and decreased levels and activity of matrix metalloproteinase enzymes suggesting that 5-azacytine may inhibit malignant spread.
Materials and methods

Cell lines, constructs and chemicals
We used HPV-(SCC61, SCC25, JHU012, and FaDu) and HPV+ (SCC090, UMSCC47, UMSCC104) HNSCC cell lines. All HPV-cells were cultured in DMEM/F12 medium supplemented with 0.4 μg/mL hydrocortisone, and all HPV+ cell lines were grown in DMEM with nonessential amino acids. All media was supplemented with 10% FBS (Invitrogen), 50 μg/mL penicillin, and 50 μg/mL streptomycin (Invitrogen). All cell lines have been tested negative for Mycoplasma and microsatellites authenticated.
To establish primary HNSCC cultures, surgical specimens were collected in PBS from consented patients within 30 min of resection. Tissue was cut into ~5 mm 3 pieces, disinfected by immersion in 70% ETOH for ~1 min, rinsed with PBS four times, and digested in 0.05% trypsin-EDTA supplemented with Collagenase type 1A (200 units/ml) (Sigma C-9722) in a vented flask at 37°C with 5% CO 2 for 10-20 min. Digestion was stopped by adding 1 volume of FBS (Sigma).
After centrifugation at 1500 rpm x 5 min, the supernatant was aspirated, the cells were resuspended in keratinocyte serum-free medium with supplements and 10% FBS, strained through a 100 μm nylon cell strainer (Falcon; Becton Dickinson Labware), plated in keratinocyte serum-free medium with supplements (GIBCO/Invitrogen) and 10% FBS onto 0.1% gelatin (Millipore) -coated plates, and grown at 37°C in a 5% CO 2 incubator. The next day, cells were washed with PBS and grown in keratinocyte serum-free medium with supplements until they reached ~90% confluence. After that, the cells were detached with 0.05% trypsin-EDTA, the reaction was stopped with defined trypsin inhibitor (Gibco), and the cells were plated onto uncoated plates in keratinocyte serum-free medium with supplements and used in experiments.
Control and p53 shRNAs in a retroviral vector were from Origene. were used to measure luminescence in the plate-reading luminometer.
5-Azacytidine, zeocin, carboplatin and pifithrin-α were obtained from Sigma.
Immunoblotting
Cells were collected by trypsinization and lysed in radioimmunoprecipitation assay (RIPA) lysis buffer (Sigma) with the addition of protease inhibitors (Roche) and phosphatase inhibitors (Sigma) for 15 minutes on ice as described (30, 31) . Frozen tissue was cut into small (~1-3 mm) pieces and homogenated in RIPA buffer. Insoluble material was removed by centrifugation at membranes. Membranes were blocked with 3% BSA in PBS and incubated with antibodies against p53, GPDH and PARP-1 (Santa Cruz) and DNMT1 from Cell Signaling. After incubation with primary antibodies, membranes were washed, incubated with secondary DyLight anti-mouse and anti-rabbit antibodies (Thermo Scientific), and signals was visualized using a Bio-Rad imager.
Zymography 100 000 of UMSCC47 or SCC090 cells were plated in growth media in 12 well plates. The next day, the cells were treated or not with 5-aza in 0.5 ml of DMEM media supplemented with 1% FBS. 24 or 48 hours after treatment the media was collected, the cells were trypsinated, collected and counted using Trypan Blue (Invitrogen). Volumes of media corresponding to 10 000 live cells were mixed with 2XNovex® Tris-Glycine SDS Sample Buffer (Invitrogen), incubated for 10 min at room temperature and loaded in Novex™ 10% Zymogram (Gelatin) Protein Gels (Invitrogen). After electrophoresis, gels were incubated in 1X Zymogram Renaturing Buffer (Invitrogen) for 30 minutes at room temperature with gentle agitation, and equilibrated in 1X Zymogram. They were exposed to developing buffer (Invitrogen) for 30 minutes at room temperature with gentle agitation, developed at 37°C in fresh developing buffer overnight and stained with SimplyBlue™ Safestain (Invitrogen).
CCL5 ELISA.
Human RANTES / CCL5 ELISA Kit was obtained from Sigma. 100 000 of UMSCC47 cells were plated in growth media in 12 well plates. The next day, the cells were treated or not with 5-aza in 0.5 ml of DMEM media supplemented with 1% FBS. 24, 48 or 72 hours after treatment the media was collected, the cells were trypsinized, collected and counted using Trypan Blue (Invitrogen). ELISA was performed according to the kit instructions, and the results were normalized to the number of cells.
Caspase Activity assay
Frozen tissue was cut into small (~1-3 mm) pieces, homogenated in cell lysis buffer and sonicated on ice. Insoluble material was removed by centrifugation at 14,000 rpm for 15 minutes at 4°C. Caspase 3/7 activity was assessed using 50 µg of lysates and Caspase-3 Activity Assay Kit (Cell Signaling) according to the instructions.
Survival assay
All cells lines, except SCC090 and primary cultures, were seeded in 12-well plates at a density of 1000 cells/well in duplicate and treated with increasing doses of 5-aza the following day. SCC090 and primary cultures were plated at a density of 10,000 cells/well. After 7 days, the cells were trypsinized and counted using Trypan Blue Solution (Invitrogen) to determine the number of live cells. Alternatively, we used Cell Titer Glo reagent (Promega). The data presented were obtained from at least 2 independent experiments. Two-tailed t-test was used to determine statistical significance of the differences between untreated cells and cells treated with the various concentrations of 5-aza.
RNA extraction and quantitative RT-PCR
Total RNA was extracted from cells, blood or tissue by Qiagen RNA extraction kit and cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad) according to the manufacturer's instructions. Quantitative real-time reverse transcription (qRT-PCR) was done using iQ SYBR Green Supermix (Bio-Rad) and primer pairs indicated in the Table S1 
Line-1 methylation
We used Global DNA Methylation LINE-1 Kit from Active Motif to assess Line-1 methylation status in cells and tumors.
In vivo experiments
The in vivo study was approved by the local animal experimental ethical committee.
Exponentially growing UMSCC47 or SCC090 cells were injected subcutaneously into the sacral area of female NUDE mice. Each mouse was inoculated with 2 × 10 5 cells in 50% matrigel and 50% PBS at a volume of 100 μL. Body weight, tumor growth, and general behavior were monitored. Tumor volumes were measured every 3 days. Mice were sacrificed when the tumor exceeded a size of 1 cm 3 .
Patient population
We used tumor specimens derived from research-consented patients with HNSCC enrolled in a window 5-aza trial (29). 
Statistical analysis
Two-way Anova analysis was used to compare 5-aza-treated and untreated mouse groups. Other statistical analyses were done using Fisher exact and t-test. Restoring p53 protein expression and tumor suppressor functions has been suggested as a promising strategy to combat HPV+ cancer, and the 5-aza structural analog 5-aza-2′-deoxycytidine (decitabine) was recently found to increase p53 protein levels in HPV+ cervical and head and neck cancer cells (32). p53 is a powerful transcription factor able to transactivate proapoptotic and growth inhibitory genes. In addition, p53 induces apoptosis through transcriptional repression of another set of genes, and through direct activation of the mitochondrial apoptotic pathway (33, 34) . To determine if 5-aza treatment enhanced p53 transactivation function, cells transiently transfected with a p53-responsive luciferase reporter were treated with 5-aza for 24 and 48 hours. After 24 and 48 hours of treatment, HPV+ UMSCC47 cells had increased p53 reporter activity. After 48 hours, 5-aza treated HPV+ HNSCC UMSCC47 cells had markedly increased p53-dependent luciferase activity (~6-fold), whereas HPV-negative and p53 wild-type UNC7 cells had a more modest increase (less than 2-fold) ( Figure 1C Increased PARP-1 cleavage was found following 5-aza treatment of UMSCC47 cells, and PARP-1 cleavage was reduced following p53 depletion by shRNA ( Figure 1F ). Together, these data suggest that apoptosis is at least partially responsible for reduced survival of HPV+ UMSCC47 cells after 5-aza, and that apoptotic cell death is partially driven by p53. Upon incorporation into DNA, 5-aza traps DNMT1 on chromatin thus removing it from the soluble fraction. The absence of DNMT1 in 5-aza treated samples confirms 5-aza incorporation ( Figure 1F ).
Results
HPV+
5-aza treatment reduces expression of all HPV genes in head and neck cancer cells.
Since p53 protein in HPV+ cells is kept at low levels through proteasomal degradation as a result of the HPV E6 oncoprotein, we determined if the increase in p53 levels following 5-aza therapy was accompanied by changes in E6 expression. Consistent with a recent report using decitabine as the demethylating agent (32), 48 or 72 hours of 5-aza treatment decreased HPV E6 expression in HPV+ HNSCC cells (Figure 2A ). High concentrations of demethylating drugs were shown to induce DNA damage in cells (27) . To test if DNA damage after 5-aza treatment contributed to 5-aza-induced p53 upregulation, we treated UMSCC47 cells with radiomimetic drug zeocin, or 1 or 3 µM of 5-aza -the concentrations that significantly downregulated HPV E6 expression. As expected, zeocin induced DNA damage, as indicated by increased phosphorylation of H2AX, and upregulated p53 protein ( Figure S2 ). Both concentrations of 5-aza trapped DNMT1 to DNA and increased p53 levels, while did not induce DNA damage ( Figure S2 ).
In contrast to zeocin, 5-aza did not phosphorylate p53 at Ser15 ( Figure S2 ).
The major HPV oncogenes, E6 and E7, are critical for HPV tumorigenesis and for evasion of apoptosis by infected cells through E6 and E7-dependent inhibition of p53 and Rb family members, respectively (36) . As was observed with HPV E6, 5-aza therapy also decreased expression of the E7 oncogene ( Figure 2B ). Although not well studied, expression levels of HPV genes in addition to E6 and E7 have been reported to alter cellular proliferation, viability and/or survival of HPV+ cancer cells (37, 38) . Expression analyses revealed that 5-aza treatment decreased expression of all HPV genes in UMSCC47 cells ( Figure 2C-2F ) and in the HPV+ head and neck cancer cell line SCC090 ( Figure S3 ). HPV+ UMSCC47 cells were also treated with DNA damaging agents (carboplatin and zeocin) to determine if decreased survival or DNA damage was sufficient to downregulate HPV gene expression. Carboplatin and zeocin therapy did not noticeably change E6 or E7 expression (Figure 2A and 2B, red) . Likewise, expression of other HPV genes was not markedly altered by carboplatin or zeocin ( Figure 2C-2F, red) . These data 
suggest that inhibition of HPV genes expression is specific to 5-aza and is not a general effect of DNA damage or cellular toxicity.
5-aza induced interferon response in some HPV+ head and neck cancer cells.
Next, we hypothesized that p53 is not the only cytotoxic pathway upregulated in HPV+ cells after 5-aza treatment, and that additional mechanisms may contribute to the increased sensitivity of HPV+ HNSCCs to demethylation. In order to determine these additional pathways, we identified genes whose expression was changed after 48 hours of 3 µM 5-aza treatment in HPV+ head and neck cancer cell lines UMSCC47 and SCC090 using Illumina microarray gene expression profiling. We found that many genes upregulated after 5-aza treatment in UMSCC47 Figure 3D ), and again, the most pronounced change in CLL5 expression after 5-aza treatment was found in UMSCC47 cells. In addition, we detected increased release of CCL5 in a growth media of UMSCC47 cells after 24, 48 or 72 hours of treatment with 5-aza ( Figure 3E ).
5-aza delays HPV+ tumor growth and inhibits proliferation in a mouse model.
To investigate activity of 5-aza against HPV+ tumors in vivo, mice bearing HPV-associated head and neck UMSCC47 or SCC090 xenografts were treated with 2 mg/kg of 5-aza. 5-aza treatment significantly suppressed the growth of tumors without causing weight loss in treated mice ( Figure 4A and B) . All mice were sacrificed on the same day when the largest tumor approached 1 cm 3 . Subsequently, mice bearing UMSCC47 tumors were sacrificed 3 days after the last dose of 5-aza and mice harboring SCC090 tumors were sacrificed on the day of their final dose. Upon sacrifice of mice, tumors were collected and stained with Ki-67 as a marker of proliferation. 5-aza inhibited proliferation in HPV+ xenografts as measured by the percentage of cells expressing Ki-67 ( Figure 5 ). Proliferation at the periphery of the tumor was inhibited in UMSCC47 from 70% to 15% and in SCC090 from 83% to 32% ( Figure 5 ). The timing of the last dose of 5-aza did not seem to greatly alter its effect on proliferation when comparing these 2 xenografted cell lines. Figure 6D and E) and casein ( Figure S5A ), which are substrates for both MMP1 and MMP10 (42) . Gelatin is also an ideal substrate for MMP2 and MMP9; however, we did not find any significant changes in the expression of MMP2 or 9 in HPV+ head and neck cancer cells after 5-aza treatment ( Figure S5B ).
5-aza inhibits expression and activity of MMPs and inhibits invasion in
Given that 5-aza treatment decreased MMP expression and secretion from HPV+ cells, we performed preliminary experiments to determine if demethylation therapy may alter the ability of HPV+ xenografted tumors to invade mouse blood vessels by assessing expression of human GPDH in cDNA isolated from blood collected from UMSCC47 tumor-bearing mice. Human GPDH mRNA was found in blood of 4 out of 5 control mice, but in only one 5-aza treated mouse ( Figure   6F ). We realize that increased human GPDH mRNA in blood could result from exosomes or free RNA; however, given the effect of demethylation on MMP expression, this result is consistent with decreased numbers of circulating tumor cells in xenograft bearing mice following 5-aza therapy.
Additional studies will be required to further characterize this effect. Together, these data provide strong evidence that 5-aza was toxic to HPV+ HNSCC and resulted in decreased proliferation and increased apoptosis. Mechanistically, 5-aza therapy inhibited expression of HPV genes and increased p53 protein levels, resulting in p53-mediated cell death (confirmed only in vitro).
Discussion
New therapies are needed for HNSCC, and HPV+ disease is a priority because of its rapidly increasing incidence. The Cancer Genome Atlas (TCGA) and others have cataloged molecular distinctions between HPV+ and HPV-HNSCC, and these differences can be mined to identify new targets. We took advantage of an epigenetic distinction of HPV+ HNSCC to test the effects of demethylation therapy in cell lines, primary cultures, xenograft mouse models, and in tumors from head and neck cancer patients treated with a short course of 5-azacytidine. Drug therapy to decrease HPV gene expression may be effective to treat HPV+ cancers, since depletion of E6 and E7 resulted in reduced cell growth and increased apoptosis. Interferon-alpha, -beta, and -gamma have been used to treat HPV diseases, but their effect on HPV gene expression is variable with increases in some cells and decreases in others (43) . Consistent with a recent report showing that demethylation decreased E6 and E7 expression (32), we showed 
that 5-aza decreased expression of all HPV16 genes, including the major oncoproteins E6 and E7 in HPV+ HNSCC (Figures 2 and 7) . In cervical cancer, E6 and E7 expression has been linked to hypermethylation and tumor invasiveness (44) (45) (46) The finding that p53 activity is stimulated by 5-aza treatment (Figure 1 ) is exciting and further speaks to the potential role of 5-aza in the treatment of HPV+ HNSCC, since reactivation of p53 has long been an attractive goal in cancer therapy (50) . Though p53 is mutated in 84% of HPV-HNSCC tumors, it is rarely mutated in HPV+ HNSCC and is instead suppressed by the HPV E6 viral oncoprotein (6) . Thus, in HPV+ HNSCC, 5-aza treatment leads to the stabilization of wildtype p53 (Figures 1 and 7) , with subsequent apoptosis (Figures 1 and 7) and inhibition of proliferation ( Figures 1, 4 and 5) . Mechanistically, the 5-aza-induced p53 reactivation is likely secondary to the downregulation of HPV E6 and release of p53 suppression, since low concentrations of 5-aza (1 or 3µM) significantly inhibited expression of HPV E6 (Figure 2 ), trapped DNMT1 to DNA, upregulated p53 (Figures 1 and S2 ), but did not induce DNA damage ( Figure   S2 ) that was shown to activate p53 in HPV+ cells (30) . However, DNA damage, induced by increasing concentrations of 5-aza (27) , can further contribute to p53 stabilization. We recently reported that HPV is not integrated in a significant portion of HPV+ HNSCC suggesting that HPV episomal maintenance is required in these tumors (8, 14) . p53 activity in cells with mutated E6 prevents HPV genome replication (51) , and likewise inhibition of E6 expression by demethylation may similarly limit HPV genome replication in cells lacking integration. Re-activation of p53 
